Vaxess is developing revolutionary technologies to change the way we receive vaccines and expand access to healthcare products.
Location: United States, Massachusetts, Boston
Total raised: $83.25M
Investors 3
Funding Rounds 6
| Date | Series | Amount | Investors |
| 13.09.2023 | - | $9M | - |
| 26.01.2023 | Series B | $10M | Mission Bi... |
| 03.11.2022 | Series B | $27M | - |
| 14.05.2021 | - | $25.3M | - |
| 01.07.2019 | Series A | $8.2M | - |
| 23.05.2013 | Series A | $3.75M | - |
Mentions in press and media 13
| Date | Title | Description |
| 22.05.2024 | Vaxess Technologies Raises $12M in Funding | Vaxess Technologies, a Cambridge, MA-based life sciences company developing a shelf-stable MIMIX skin patch for vaccines and therapeutics, raised $12M in funding. Backers included RA Capital Management, Engine Ventures, GHIC, and Mission Bi... |
| 13.09.2023 | Vaxess Technologies Raises $9M in Funding | Vaxess Technologies, Inc., a Cambridge, MA-based life sciences company developing a shelf-stable vaccine patch with potential for self-application, raised an additional $9m in venture capital funding. Backers included RA Capital, The Engine... |
| 11.01.2023 | Vaxess Raises Additional $10M for Needle-Free Vaccine Patches Jobs at Vaxess Technologies | Photo: Vaxess / Facebook Vaxess is a Cambridge-based life sciences company developing a shelf-stable vaccine patch. In November, the company raised $27 million to fund clinical trials for its tech. A few months later, Vaxess raised an addit... |
| 10.01.2023 | Vaxess Raises Additional $10M in Funding | Vaxess, a Cambridge, MA-based life sciences company developing a shelf-stable vaccine patch with potential for self-application, raised additional $10M in funding. The round was led by RA Capital, The Engine, and Mission BioCapital. The com... |
| 03.11.2022 | Vaxess Raises $27M in Series B Funding | Vaxess Technologies, a Cambridge, MA-based life sciences company developing a sustained-release vaccine patch, raised $27M in Series B funding. The round was led by RA Capital Management with participation from MIT’s The Engine, Mission Bio... |
| 29.01.2021 | Ted Hibben joins Vaxess as Chief Business Officer | Vaxess Logo As Vaxess moves the first program into the clinic, we’re excited to work with Ted to expand the pipeline into a broad range of prophylactic and therapeutic programs in infectious diseases, oncology and beyond. CAMBRIDGE, Mass. (... |
| 01.07.2019 | Vaxess Technologies Closes Final Tranche of $8.2M Series A Funding | Vaxess Technologies, a Cambridge, MA-based biotechnology company, closed the final tranche of an $8.2m Series A funding round. The round was led by The Engine, which included participation from Bioinnovation Capital. The company, which has ... |
| 28.06.2019 | Term Sheet — Friday June 28 | APPLE’S AUTONOMOUS VEHICLE AMBITIONS Hello Term Sheet readers. Lucinda here again until Polina’s return following the July 4 holidays. In the meantime, please send deals to lucinda.shen@fortune.com. Paid Content You can't secure what you ca... |
| 28.06.2019 | Boston Tech Watch: Vaxess, Fusion Power, Wayfair & MassChallenge | Share Share on Facebook Share on Twitter LinkedIn Email Reprints An acquisition, accelerator awards, access to venture capital, and arguments over e-commerce sales to migrant detention centers. All that and more in this week’s Boston tech n... |
| 27.06.2019 | Vaxess Technologies Closes Final Tranche of $8.2 Million Series A and Appoints Dr. Purnanand Sarma to the Board | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vaxess Technologies, a biotechnology company redefining drug delivery with the silk-powered MIMIX smart release patch, today announced it has closed the final tranche of an $8.2 million Series A round. Led... |
Show more